In a BC study with TMA samples, 53% of PD-L1+ cases expressed LAG-3, and the proportion of concurrent LAG-3+ and CD8+, and PD-L1+ and CD8+, were 26% and 18%, respectively (data on TNBC were not available). This evidence concerns the gene CD8A and breast cancer.